Ashby C R, Minabe Y, Stemp G, Hagan J J, Middlemiss D N
Department of Pharmaceutical Health Sciences, College of Pharmacy and Allied Health Professions, St. John's University, Jamaica, NY 11439, USA.
J Pharmacol Exp Ther. 2000 Sep;294(3):1166-74.
This study examined the effect of acute and repeated p.o. administration of the selective D(3) receptor antagonist SmithKline Beecham (SB)-277011-A (1, 3, or 10 mg/kg) on the activity of spontaneously active midbrain dopamine (DA) neurons in anesthetized, male Sprague-Dawley rats. This was accomplished with the technique of in vivo extracellular single-unit recording. A single administration of either 3 or 10 mg/kg SB-277011-A produced a significant increase in the number of spontaneously active substantia nigra pars compacta (or A9) DA neurons compared with vehicle-treated (2% methylcellulose) animals. The 10-mg/kg dose of SB-277011-A produced a significant increase in the number of spontaneously active A10 DA neurons compared with vehicle-treated animals. The acute administration of SB-277011-A produced a significantly greater alteration in the firing pattern of spontaneously active A10 DA neurons, particularly at the 3- and 10-mg/kg doses, compared with vehicle-treated animals. The i.v. administration of SB-277011-A (0.01-1.28 mg/kg) did not significantly alter the firing rate or firing pattern of either A9 or A10 DA neurons. The repeated p.o. administration of 1, 3, or 10 mg/kg SB-277011-A once a day for 21 days produced a significant decrease in the number of spontaneously active A10 DA neurons. The repeated administration of SB-277011-A produced a greater effect on the firing pattern of spontaneously active A10 DA neurons, particularly at the 3-mg/kg dose, compared with A9 DA neurons. Overall, our results indicate that SB-277011-A alters the activity of midbrain DA neurons in rats.
本研究检测了选择性D(3)受体拮抗剂史克必成(SB)-277011-A(1、3或10毫克/千克)急性和重复口服给药对麻醉的雄性斯普拉格-道利大鼠中脑自发活动的多巴胺(DA)神经元活性的影响。这是通过体内细胞外单单位记录技术完成的。与溶剂处理(2%甲基纤维素)的动物相比,单次给予3或10毫克/千克SB-277011-A可使黑质致密部(或A9)自发活动的DA神经元数量显著增加。与溶剂处理的动物相比,10毫克/千克剂量的SB-277011-A可使A10自发活动的DA神经元数量显著增加。与溶剂处理的动物相比,SB-277011-A的急性给药对A10自发活动的DA神经元的放电模式产生了显著更大的改变,尤其是在3和10毫克/千克剂量时。静脉注射SB-277011-A(0.01 - 1.28毫克/千克)对A9或A10 DA神经元的放电频率或放电模式没有显著影响。每天一次重复口服给予1、3或10毫克/千克SB-277011-A,持续21天,可使A10自发活动的DA神经元数量显著减少。与A9 DA神经元相比,重复给予SB-277011-A对A10自发活动的DA神经元的放电模式产生了更大的影响,尤其是在3毫克/千克剂量时。总体而言,我们的结果表明SB-277011-A可改变大鼠中脑DA神经元的活性。